Literature DB >> 29731245

The prognostic impact of primary tumor resection in pancreatic neuroendocrine tumors with synchronous multifocal liver metastases.

Chen Lin1, Hongmei Dai2, Xiafei Hong3, Haiyu Pang4, Xianze Wang5, Peiran Xu6, Jialin Jiang7, Wenming Wu8, Yupei Zhao9.   

Abstract

BACKGROUND: Whether primary tumor resection benefits patients with synchronous multifocal liver metastases from pancreatic neuroendocrine tumors remains controversial. We investigated whether primary tumor resection significantly affects survival in this study.
METHODS: A retrospective study of patients with synchronous multifocal liver metastases from pancreatic neuroendocrine tumors between 1998 and 2016 was performed. Patient demographics, operation details, adjuvant treatment, and pathological and survival information were collected, and relevant clinical-pathological parameters were assessed in univariate and multivariate survival analyses.
RESULTS: Sixty-three patients were included in this study, including 35 who underwent primary tumor resection. The median survival time and 5-year survival rate of this cohort were 50 months and 44.5%, respectively. Median survival time in the resected group was significantly longer at 72 months than that of 32 months in the nonresected group (p = 0.010). Multivariate analysis showed that primary tumor surgery was a significant independent prognostic factor (HR 0.312, 95% CI: 0.128-0.762, p = 0.011).
CONCLUSIONS: Primary tumor resection significantly benefits patients with synchronous multifocal liver metastases from pancreatic neuroendocrine tumors.
Copyright © 2018 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Multifocal liver metastases; Pancreatic neuroendocrine tumors; Primary tumor resection; Prognosis; Synchronous

Year:  2018        PMID: 29731245     DOI: 10.1016/j.pan.2018.04.014

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  4 in total

Review 1.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

2.  A Nomogram to Accurately Identify Pancreatic Neuroendocrine Tumors Metastasizing to Distant Organs: A Study Based on Two National Population-Based Cohorts From the United States and China.

Authors:  Xianbin Zhang; Lili Lu; Jun Liu; Weihan Liu; Li Li; Yushan Wei; Jinhu Fan; Li Ma; Peng Gong
Journal:  Clin Med Insights Oncol       Date:  2022-05-19

3.  Palliative resection of primary site in advanced gastroenteropancreatic neuroendocrine tumors improves survivals.

Authors:  Derya Kıvrak Salim; Selami Bayram; İsmail Gömceli; Ayhan Hilmi Çekin; Mustafa Karaca; Murat Koçer; Mustafa Yıldız
Journal:  Turk J Gastroenterol       Date:  2019-10       Impact factor: 1.852

4.  Treatment options for PNET liver metastases: a systematic review.

Authors:  Giuseppe Nigri; Niccolò Petrucciani; Tarek Debs; Livia Maria Mangogna; Anna Crovetto; Giovanni Moschetta; Raffaello Persechino; Paolo Aurello; Giovanni Ramacciato
Journal:  World J Surg Oncol       Date:  2018-07-14       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.